Akcijų birža > Fundamentali analizė > OLF1R

* Čia ir toliau: Lietuvos įmonių rodikliai pateikti litais, Latvijos – latais, Estijos – eurais.

OLF1R - Olainfarm

Nuo iki

Pagrindiniai finansiniai rodikliai (LVL)

Kaina P/BV P/E P/S GPM,% Grynasis pelnas, M Akcijų sk.
5.90 LVL 3.51 55.21 8.53 15.83 1.51 14 085 078

Kap., M Pardavimai, M EPS Buhalterinė vertė Pardavimai akcijai EBIT, M EBITDA, M
83.10 9.74 0.35 1.68 2.16 2.08 2.55

46.23 7.16 5.54 23.40 13.99 3.91

Paskutinė ataskaita



2013-05-16 09:45 OLF: Investor Conference Webinar about Olainfarm’s recent developments
2013-05-15 16:00 OLF: Olainfarm will Hold Investor Conference Webinar about Recent Developments
2013-05-15 16:00 OLF: Sales of OlainFarm in April Reaches 3.78 Million Lats
2013-05-09 08:51 OLF: Olainfarm will Hold Investor Conference Webinar about Recent Developments
2013-05-08 09:00 OLF: OlainFarm to Receive Corporate Income Tax Exemption for 5.21 Million Lats.
2013-05-03 10:51 OLF: CORRECTION: Resolutions of the AGM (payment date corrected)
2013-05-02 10:41 OLF: OlainFarm has Acquired 47.5% of Shares in Silvanols
2013-04-19 09:33 OLF: OlainFarm Fully Resumes Production of MAG and Nitrofuranes.
2013-04-17 11:14 OLF: OlainFarm announcement
2013-04-12 16:48 OLF: Draft resolutions of the Annual General Meeting of Shareholders of JSC „Olainfarm” to be held on April 29th, 2013:

Informacija apie įmonę

Name: AS "Olainfarm"
Core business: Pharmaceuticals
Auditor: Ernst & Young Baltic
Date of listing: 09.06.1997. (I-list)
From 01.12.2006 Main list

Background information:
Olaine Chemical-Pharmaceutical Plant was established in October 10, 1972 as a state enterprise. At the beginning, the factory manufactured only biologically active substances. Later it also started manufacturing finished pharmaceuticals, and the factory became one of the largest chemical-pharmaceutical enterprises in the Soviet Union producing more than 25 products.
JSC Olaine Chemical-Pharmaceutical Plant is the largest chemical - pharmaceutical manufacturer in the Baltic States. The main activities of the company are:
- production of high quality biologically-active and other chemical compounds through organic synthesis, both for the existing products and customised orders (contract manufacturing);
- production of finished pharmaceuticals from self-synthesised, as well as purchased substances, mostly in the form of tablets and capsules.
Presently JSC Olainfarm manufactures 78 finished pharmaceuticals and 35 different active pharmaceutical substances and chemical intermediaries.
The main export markets for the company are the CIS states (Russia, the Ukraine, Byelorussia etc.) accounting for more than half of total output. Export of products to the European Union is less than 10%. Russian crisis of 1998 created the need for reorientation of market priorities, as it had a substantially negative effect on the company’s performance and its shares’ prices. In 1998 the company started the actual re-orientation towards the Western markets. At present contracts for manufacturing of chemical intermediates are concluded with several Western companies.
JSC "Olainfarm" Terms of share capital increase
JSC "Olainfarm" Terms of share capital increase, 2007
Shareholder&5_039;s application for subscription for the use of preemptive rights, 2007
Address: Rūpnīcu iela 5, Olaine
Phone: + 371 67013700
Fax: + 371 67013777
Internet: www.olainfarm.lv
E-mail: [email protected]
Contactperson: Salvis Lapiņš
Phone: + 371 67013717
Fax: + 371 67013777
E-mail: [email protected]


Salvis Lapiņš Member of the Board
Inga Liščika Member of the Board
Jurijs Kaplinovs Member of the Board
Jeļena Borcova Member of the Board
Valērijs Maligins Chairman of the Board
Salvis Lapiņš Member of the Supervisory Council
Signe Baldere-Sildedze Member of the Supervisory Council
Volodimirs Krivozubovs Member of the Supervisory Council
Aleksandrs Raicis Member of the Supervisory Council
Eļena Dudko Deputy Chairperson of the Council
Helmuts Balderis-Sildedzis Chairman of the Council

Pagrindiniai akcininkai

SIA Olmafarm 42.56% (5.99 M)
AS Swedbank clients account 7.93% (1.12 M)
Kiti akcininkai 23.34% (3.29 M)

NASDAQ Vilnius akcijų Fundamentali Analizė

NASDAQ Vilnius akcijų Fundamentali Analizė